7081 research outputs found
Sort by
Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration
No full textPredictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms
No full textWhen the brain fades before the eye: encephalopathy as a rare presentation of direct carotid-cavernous fistula
No full textHigh-risk Obstructive sleep apnea (OSA), insomnia, and comorbid OSA (COMISA) increase likelihood of poor functional status in neurological and psychiatric populations
No full text
Bridging the gut and the heart-Exploring pathophysiology, risk factors, and therapeutic implications of cardiovascular disease in inflammatory bowel disease
No full textEstimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
No full textPurpose: Lung cancer remains a leading cause of cancer-related mortality. Tumor Treating Fields (TTFields) therapy extended survival in patients with metastatic non-small cell lung cancer (NSCLC) on or after platinum-based therapy. This study evaluates the cost-effectiveness of TTFields therapy concomitant with immune checkpoint inhibitors (ICIs) or docetaxel.
Methods: A model-based health economic evaluation estimated lifetime costs, clinical benefits, and humanistic outcomes of TTFields therapy plus ICI or docetaxel versus ICI or docetaxel alone in metastatic NSCLC. The model used clinical data from the LUNAR study, US healthcare cost data, and quality-adjusted life year (QALY) measures.
Results: The addition of TTFields therapy to an ICI or docetaxel resulted in a mean life-year gain of 0.92 and a QALY gain of 0.66, with an incremental cost-effective ratio (ICER) of 58,764 per QALY gained. For TTFields therapy plus docetaxel, the life-year gain was 0.23 and the QALY gain was 0.17, with an ICER of $306,029 per QALY gained. Sensitivity analyses confirmed the robustness of these findings.
Conclusion: The addition of TTFields therapy to an ICI or docetaxel in metastatic NSCLC demonstrates comparable cost-effectiveness to other approved treatments. ICERs fall within the accepted range for US cost-effectiveness thresholds, supporting their use in clinical practice. TTFields therapy extended mean lifetime survival, offering a clinically meaningful and economically justifiable option for patients progressing after platinum-based chemotherapy
Impact of Social Determinants of Health on Cancer Treatment Referrals in Patients Living with HIV in the United States: A Narrative Review
No full textRetired Nurse
No full texthttps://scholarlycommons.baptisthealth.net/one-map-limitless-destintions-2025/1057/thumbnail.jp
Hospitalist Nurse Practitioner
No full texthttps://scholarlycommons.baptisthealth.net/one-map-limitless-destintions-2025/1052/thumbnail.jp